Gallbladder Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE FOR SURGICAL RESECTION:

• Histologically confirmed gallbladder carcinoma (adenocarcinoma, papillary, mucinous variants) staged T1b to T3 (AJCC 8th Edition)

• ECOG performance status 0–2

• Adequate hepatic reserve: future liver remnant (FLR) ≥30% of total functional liver volume (assessed by CT volumetry)

• No distant metastases (M0) on staging workup

• No encasement of main portal vein or hepatic artery (or technically reconstructible involvement)

• CA 19-9 and CEA within oncologically acceptable parameters relative to disease burden

• CANDIDATES FOR NEOADJUVANT / BORDERLINE RESECTABLE PROTOCOLS:

• T3–T4 disease with portal vein or bile duct involvement amenable to downstaging

• Incidentally discovered GBC post-cholecystectomy (T1b or higher) requiring re-resection

• REQUIRED DIAGNOSTIC WORK-UP PRIOR TO TRAVEL:

• High-resolution contrast-enhanced CT (chest, abdomen, pelvis) — triple-phase protocol

• MRI/MRCP (gadoxetate-enhanced) for hepatic parenchymal and biliary anatomy

• 18F-FDG PET-CT scan for nodal and occult metastatic disease

• Endoscopic ultrasound (EUS) for regional lymph node staging if CT-equivocal

• Liver function tests, coagulation profile (INR, PT), full blood count, metabolic panel

• Tumour markers: CA 19-9, CEA, AFP

• Next-generation sequencing (NGS) or tumour molecular profiling (ERBB2, FGFR, IDH1, BRAF, MSI/MMR) — increasingly standard at GAF partner centres

• Histopathology report with IHC panel (CK7, CK20, CDX2, p53)

• ECHO (echocardiogram) and pulmonary function tests (PFTs) pre-operatively, especially for patients >60 or with cardiac history

• CONTRAINDICATIONS / EXCLUSION CRITERIA:

• Stage IVB disease (distant organ metastases not amenable to curative-intent resection)

• Peritoneal carcinomatosis (relative contraindication; some centres offer HIPEC in select cases)

• Child-Pugh C cirrhosis or severe hepatic dysfunction

• ECOG performance status ≥3

• Active uncontrolled infection, bleeding diathesis, or prohibitive cardiopulmonary comorbidity

• Prior biliary stenting causing peritoneal seeding (port-site or bile spillage in prior laparoscopic cholecystectomy — must be declared and assessed)

SURGICAL APPROACHES:

1. SIMPLE CHOLECYSTECTOMY (T1a only): Acceptable for incidental T1a tumours confined to the lamina propria with clear margins on frozen section. Laparoscopic technique is standard. No re-resection required.

2. RADICAL CHOLECYSTECTOMY WITH HEPATIC RESECTION (T1b–T3, primary standard): En-bloc resection of the gallbladder with a 2–3 cm margin of hepatic parenchyma involving segments IVb and V. Accompanied by systematic lymphadenectomy of the hepatoduodenal ligament (portal hepatis), including pericholedochal, cystic duct, right hepatic artery, and anterior/posterior portal vein nodes (minimum 6 nodes for adequate staging). Bile duct excision with Roux-en-Y hepaticojejunostomy reconstruction is added when bile duct margin involvement is confirmed on frozen section or when achieving a clear cystic duct margin is not feasible.

3. EXTENDED HEPATIC RESECTION (T3–T4 with vascular or extensive hepatic involvement): Right hepatectomy or right trisectionectomy may be required for advanced local disease. Portal vein embolisation (PVE) is performed 4–6 weeks pre-operatively when FLR is inadequate (<30%). In selected centres, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is employed.

4. MINIMALLY INVASIVE / ROBOTIC SURGERY: Laparoscopic and robotic-assisted radical cholecystectomy (da Vinci Xi system) are performed at high-volume Indian and UAE centres for appropriately selected patients (T1b–T2, no vascular involvement). Robotic platforms offer superior 3D visualisation, wristed instrument articulation, and tremor filtration — particularly advantageous for precise hepatic parenchymal dissection and lymphadenectomy in the hepatoduodenal ligament. Published data show equivalent oncological outcomes with significantly reduced blood loss, shorter hospital stays, and faster return to systemic therapy eligibility.

5. PALLIATIVE / NON-SURGICAL INTERVENTIONS:

• Biliary drainage: Endoscopic retrograde cholangiopancreatography (ERCP) with plastic or metal stent insertion, or percutaneous transhepatic biliary drainage (PTBD) for obstructive jaundice in unresectable cases

• Transarterial chemoembolisation (TACE): Used in select unresectable cases with predominantly hepatic disease

• Stereotactic body radiotherapy (SBRT): Increasingly used for local control in unresectable or oligometastatic GBC at specialised centres

• Photodynamic therapy (PDT): For intraluminal biliary palliation at select centres

SYSTEMIC THERAPY PROTOCOLS:

• First-Line (Advanced/Metastatic): Gemcitabine 1000 mg/m² + Cisplatin 25 mg/m² (Days 1, 8 every 21 days) + Durvalumab 1500 mg (Day 1 every 21 days) — TOPAZ-1 regimen; now standard of care per ESMO/ASCO 2023 guidelines

• Alternatively: FOLFOX (oxaliplatin + leucovorin + 5-FU) as per ABC-06 trial for second-line or cisplatin-ineligible patients

• Adjuvant Chemotherapy: Capecitabine monotherapy for 6 months post-resection (BILCAP trial) is the current standard for R0/R1 resected patients

• Targeted Therapy: ERBB2 (HER2) amplification (~15–20% of GBC) — trastuzumab-based regimens or tucatinib combinations under investigation; IDH1 mutations — ivosidenib; FGFR alterations — pemigatinib or infigratinib; BRAF V600E — dabrafenib + trametinib

• Immunotherapy: Pembrolizumab for MSI-H/dMMR tumours (TMB-H); Nivolumab combinations in clinical trials

• Tumour Mutational Burden (TMB) and PD-L1 expression guide immunotherapy eligibility

RADIATION THERAPY:

• External beam radiotherapy (EBRT) with concurrent capecitabine or 5-FU for R1 resection margins or unresectable local disease

• Intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT) are available at partner centres, offering precise dose delivery with sparing of adjacent bowel and liver

PHASE 1 — PRE-TRAVEL WORKUP (2–4 weeks before departure):

• Patient submits medical records to GAF Healthcare case manager: histopathology, imaging (CT/MRI/PET-CT), blood reports, operative reports if prior cholecystectomy

• GAF connects patient with assigned hepatobiliary oncology team at chosen centre (India or UAE)

• Telemedicine consultation conducted: tumour board review, resectability assessment, staging confirmation, NGS report review

• Travel plan confirmed: visa category arranged (e-Medical Visa for India; visit/medical visa for UAE), treatment dates locked

• Insurance pre-authorisation initiated where applicable

PHASE 2 — ARRIVAL & PRE-OPERATIVE EVALUATION (Days 1–3 in-country):

• Airport pickup by GAF-assigned driver; check-in to partner hospital or accommodation

• Repeat or supplementary imaging at destination centre if required (gadoxetate MRI, EUS)

• Anaesthesiology and cardiology pre-operative clearance; ECHO, spirometry, coagulation studies

• Tumour board conference — surgical and medical oncology alignment

• Nutritional assessment; high-protein pre-operative nutrition protocol initiated (ERAS — Enhanced Recovery After Surgery pathway)

• Biliary drainage (PTBD or ERCP stenting) if pre-operative jaundice present and bilirubin >3 mg/dL

• PVE performed if FLR inadequate (4–6 week wait period may be required before major hepatic resection)

• Informed consent; anaesthesia discussion

PHASE 3 — SURGICAL PROCEDURE (Day 3–5):

• General anaesthesia; intraoperative ultrasound to confirm hepatic margins and vascular anatomy

• Radical cholecystectomy with hepatic resection (laparoscopic/robotic or open, per plan); operative time typically 3–6 hours

• Intraoperative frozen section of cystic duct and hepatic margins to confirm R0 resection

• Systematic lymphadenectomy; bile duct excision + hepaticojejunostomy if indicated

• Abdominal drain placement; closure

PHASE 4 — EARLY POST-OPERATIVE RECOVERY (Days 1–7 post-surgery):

• ICU or HDU monitoring for 24–48 hours; liver function monitoring, drain output, fluid balance

• Enhanced Recovery After Surgery (ERAS) protocol: early mobilisation Day 1, liquid diet by Day 2, soft diet by Day 3

• IV analgesia transitioned to oral; anti-nausea and proton pump inhibitor (PPI) medications

• Deep vein thrombosis (DVT) prophylaxis: LMWH injections and compression stockings from Day 1

• Drain removed Day 4–7 when output <100 mL/day (bilious or serous)

• For robotic/laparoscopic cases: discharge typically Day 5–7; open major hepatectomy: Day 8–12

PHASE 5 — IN-COUNTRY RECOVERY & ADJUVANT THERAPY INITIATION (Weeks 2–6):

• Weekly outpatient oncology reviews; wound check, LFT monitoring, CA 19-9 trending

• Post-operative restaging CT/MRI at Week 4–6 to confirm R0 status and detect early recurrence

• Adjuvant capecitabine initiated typically 6–8 weeks post-operatively in R0/R1 resected patients

• First cycle of systemic chemotherapy (if required) may be administered at the treating centre before departure

• Nutritional counselling, physiotherapy, and hepatology follow-up

• Psychological support and survivorship care planning provided by GAF partner centres

PHASE 6 — FIT-TO-FLY CLEARANCE & DEPARTURE (Weeks 4–8):

• Fit-to-fly assessed by treating surgical and oncology team based on: wound healing, drain removal, absence of bile leak or hepatic insufficiency, stable LFTs, DVT prophylaxis completion, and patient mobility

• Straightforward radical cholecystectomy (laparoscopic): fit-to-fly at 4–5 weeks

• Major open hepatic resection: fit-to-fly at 6–8 weeks

• Comprehensive discharge summary, imaging CDs, pathology blocks, and ongoing chemotherapy protocol provided for home oncologist

• GAF Healthcare facilitates telemedicine follow-up at 1 month, 3 months, and 6 months post-discharge